Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
13 evidence topics · 11 sources
Single ascending doses of oral solution in healthy volunteers: absorption, dose proportionality, and half-life
Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters
| Parameter | 1 mg fasted | 2 mg fasted | 4.5 mg fasted | 12 mg fasted | 22 mg fasted | 22 mg after high-calorie, high-fat breakfast |
|---|---|---|---|---|---|---|
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |
| CL/F, L/h, mean (SD) | “42.3 (25.4)” | “33.8 (11.9)” | “37.6 (11.1)” | “40.9 (20.7)” | “31.5 (5.60)” | “25.3 (9.77)” |
Food effect after a single 22 mg dose of oral solution
Company summary of phase 1 pharmacokinetics with and without food
Population pharmacokinetic model from the bradykinin challenge study
Immediate-release capsule 2 x 10 mg in healthy volunteers
Immediate-release capsule in adults with HAE in a non-attack state (RAPIDe-1 part 1)
Immediate-release capsule 2 x 20 mg compared with the extended-release tablet 40 mg in healthy volunteers (PHA022121-C020)
| Parameter | Deucrictibant IR capsule 2 x 20 mg | Deucrictibant XR tablet 40 mg |
|---|---|---|
| Cmax, ng/mL, mean (SD) | “547 (193)” | “87.2 (25.5)” |
| tmax, hours, median (range) | “1.00 (0.50–1.50)” | “5.03 (3.98–24.00)” |
| AUCinf, ng⋅h/mL, mean (SD) | “1799 (745)” | “1547 (699)” |
| t1/2, hours, mean (SD) | “5.10 (1.28)” | “5.72 (1.70)” |
| CL/F, L/hours, mean (SD) | “26.5 (12.7)” | “31.5 (14.7)” |